Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
ConditionDiabetes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2+
SponsorDexCom, Inc.
About this trial
"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling
Has at least one HbA1C (Hemoglobin a1c) measurement within three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use
Subject is willing and able to use Dexcom CGM System according to approved product labeling
Subject is willing and able to complete applicable patient reported outcome assessments/ surveys
Disqualifiers
Is contraindicated for a Dexcom CGM System per approved commercial labeling
In the Investigator's opinion, the subject is not considered to be a suitable candidate
Trial population
The clinical study population will consist of up to 5000 subjects.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Dexcom CGM G6/G6 Pro/G7
DeviceDexcom CGM G6/G6 Pro/G7 device
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Patient Reported Outcomes (PROs)
Patients will be asked to complete multiple questionnaires over a period of 4 years for data to be analyzed and reported.
Time frame
4 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov